誉衡药业
(002437)
| 流通市值：54.33亿 | | | 总市值：56.54亿 |
| 流通股本：21.91亿 | | | 总股本：22.80亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,857,506,712.57 | 1,221,310,646.18 | 593,133,301.68 | 2,626,039,306.71 |
| 营业收入 | 1,857,506,712.57 | 1,221,310,646.18 | 593,133,301.68 | 2,626,039,306.71 |
| 二、营业总成本 | 1,686,482,833.11 | 1,108,279,372.88 | 553,364,313.22 | 2,489,293,946.97 |
| 营业成本 | 868,397,419.79 | 561,414,572.52 | 273,973,435.86 | 1,092,711,083.38 |
| 税金及附加 | 25,272,388.83 | 17,076,223.61 | 7,056,258.68 | 36,118,668.2 |
| 销售费用 | 631,722,798.46 | 428,159,677.58 | 219,368,874.09 | 1,068,518,701.16 |
| 管理费用 | 110,018,674.56 | 72,367,728.16 | 36,935,856.14 | 175,194,905.35 |
| 研发费用 | 48,755,362.8 | 28,104,239.15 | 14,704,935.33 | 85,438,221.66 |
| 财务费用 | 2,316,188.67 | 1,156,931.86 | 1,324,953.12 | 31,312,367.22 |
| 其中:利息费用 | 8,734,869.94 | 7,742,103.02 | 5,239,020.43 | 42,654,181.13 |
| 其中:利息收入 | 7,888,828.78 | 6,213,323.42 | 3,832,066.76 | 18,473,913.07 |
| 加:公允价值变动收益 | -5,108,803.07 | -10,876,265.5 | -11,405,713.07 | -17,934,320.91 |
| 加:投资收益 | 5,987,857.43 | 6,027,960.63 | 687,179.41 | -23,438,023.69 |
| 资产处置收益 | 1,587,450.4 | -16,446.85 | - | 2,839,189.27 |
| 资产减值损失(新) | -585,236.29 | -585,236.29 | - | -3,303,703.22 |
| 信用减值损失(新) | 1,208,038.24 | 863,829.93 | 534,388.22 | 2,061,254.22 |
| 其他收益 | 48,187,810.86 | 44,820,969.16 | 38,864,209.88 | 78,076,856.55 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 222,300,997.03 | 153,266,084.38 | 68,449,052.9 | 175,046,611.96 |
| 加:营业外收入 | 103,541 | 71,493.97 | 29,737.34 | 2,660,841.44 |
| 减:营业外支出 | 346,651.03 | 268,343.41 | 65,236.54 | 929,304.48 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 222,057,887 | 153,069,234.94 | 68,413,553.7 | 176,778,148.92 |
| 减:所得税费用 | 30,271,571.05 | 21,543,456.65 | 12,652,518.21 | 48,077,508.19 |
| 六、净利润 | 191,786,315.95 | 131,525,778.29 | 55,761,035.49 | 128,700,640.73 |
| 持续经营净利润 | 191,786,315.95 | 131,525,778.29 | 55,761,035.49 | 128,700,640.73 |
| 归属于母公司股东的净利润 | 183,485,762.41 | 124,970,766.54 | 52,282,909.59 | 120,334,186.37 |
| 少数股东损益 | 8,300,553.54 | 6,555,011.75 | 3,478,125.9 | 8,366,454.36 |
| (一)基本每股收益 | 0.08 | 0.06 | 0.02 | 0.05 |
| (二)稀释每股收益 | 0.08 | 0.06 | 0.02 | 0.05 |
| 八、其他综合收益 | -388,301 | 225,425.69 | 71,328.17 | 855,100.9 |
| 归属于母公司股东的其他综合收益 | -388,301 | 225,425.69 | 71,328.17 | 855,100.9 |
| 九、综合收益总额 | 191,398,014.95 | 131,751,203.98 | 55,832,363.66 | 129,555,741.63 |
| 归属于母公司股东的综合收益总额 | 183,097,461.41 | 125,196,192.23 | 52,354,237.76 | 121,189,287.27 |
| 归属于少数股东的综合收益总额 | 8,300,553.54 | 6,555,011.75 | 3,478,125.9 | 8,366,454.36 |
| 公告日期 | 2024-10-29 | 2024-08-24 | 2024-04-27 | 2024-04-20 |
| 审计意见(境内) | | | | 标准无保留意见 |